vs
Side-by-side financial comparison of Origin Bancorp, Inc. (OBK) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $57.3M, roughly 1.8× RHYTHM PHARMACEUTICALS, INC.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs -83.0%, a 109.6% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 3.9%).
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
OBK vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.0M | $57.3M |
| Net Profit | $27.7M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 26.6% | -83.0% |
| Revenue YoY | — | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $0.89 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $103.4M | $57.3M | ||
| Q3 25 | $109.8M | $51.3M | ||
| Q2 25 | $83.5M | $48.5M | ||
| Q1 25 | $94.1M | $32.7M | ||
| Q4 24 | $78.3M | $41.8M | ||
| Q3 24 | $90.8M | $33.3M | ||
| Q2 24 | $96.4M | $29.1M |
| Q1 26 | $27.7M | — | ||
| Q4 25 | $29.5M | $-47.5M | ||
| Q3 25 | $8.6M | $-52.9M | ||
| Q2 25 | $14.6M | $-46.6M | ||
| Q1 25 | $22.4M | $-49.5M | ||
| Q4 24 | $14.3M | $-43.3M | ||
| Q3 24 | $18.6M | $-43.6M | ||
| Q2 24 | $21.0M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | — | ||
| Q4 25 | 36.2% | -82.2% | ||
| Q3 25 | 10.0% | -102.6% | ||
| Q2 25 | 22.3% | -93.4% | ||
| Q1 25 | 30.4% | -143.7% | ||
| Q4 24 | 23.0% | -98.6% | ||
| Q3 24 | 26.1% | -132.0% | ||
| Q2 24 | 27.7% | -139.2% |
| Q1 26 | 26.6% | — | ||
| Q4 25 | 28.5% | -83.0% | ||
| Q3 25 | 7.9% | -103.1% | ||
| Q2 25 | 17.5% | -96.1% | ||
| Q1 25 | 23.8% | -151.4% | ||
| Q4 24 | 18.2% | -103.6% | ||
| Q3 24 | 20.5% | -131.2% | ||
| Q2 24 | 21.8% | -110.9% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.95 | $-0.73 | ||
| Q3 25 | $0.27 | $-0.82 | ||
| Q2 25 | $0.47 | $-0.75 | ||
| Q1 25 | $0.71 | $-0.81 | ||
| Q4 24 | $0.45 | $-0.71 | ||
| Q3 24 | $0.60 | $-0.73 | ||
| Q2 24 | $0.67 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $139.1M |
| Total Assets | $10.2B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $424.2M | $388.9M | ||
| Q3 25 | $626.9M | $416.1M | ||
| Q2 25 | $334.1M | $291.0M | ||
| Q1 25 | $486.2M | $314.5M | ||
| Q4 24 | $470.2M | $320.6M | ||
| Q3 24 | $321.2M | $298.4M | ||
| Q2 24 | $288.1M | $319.1M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $139.1M | ||
| Q3 25 | $1.2B | $148.8M | ||
| Q2 25 | $1.2B | $-11.9M | ||
| Q1 25 | $1.2B | $18.9M | ||
| Q4 24 | $1.1B | $21.7M | ||
| Q3 24 | $1.1B | $11.2M | ||
| Q2 24 | $1.1B | $39.3M |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $9.7B | $480.2M | ||
| Q3 25 | $9.8B | $506.9M | ||
| Q2 25 | $9.7B | $372.7M | ||
| Q1 25 | $9.8B | $386.7M | ||
| Q4 24 | $9.7B | $392.3M | ||
| Q3 24 | $10.0B | $363.6M | ||
| Q2 24 | $9.9B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $158.9M | $-25.4M | ||
| Q3 25 | $59.3M | $-26.6M | ||
| Q2 25 | $20.6M | $-23.3M | ||
| Q1 25 | $35.6M | $-40.4M | ||
| Q4 24 | $108.5M | $-18.8M | ||
| Q3 24 | $39.6M | $-25.2M | ||
| Q2 24 | $11.9M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $151.1M | — | ||
| Q3 25 | $56.8M | — | ||
| Q2 25 | $19.6M | — | ||
| Q1 25 | $34.8M | — | ||
| Q4 24 | $86.4M | — | ||
| Q3 24 | $32.2M | — | ||
| Q2 24 | $6.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 146.0% | — | ||
| Q3 25 | 51.7% | — | ||
| Q2 25 | 23.5% | — | ||
| Q1 25 | 37.0% | — | ||
| Q4 24 | 110.3% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 6.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | 5.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.38× | — | ||
| Q3 25 | 6.88× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 7.60× | — | ||
| Q3 24 | 2.13× | — | ||
| Q2 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
RYTM
Segment breakdown not available.
